In the FGFR3‐mutant myeloma cell line KMS‐11, this produced a stable resistant derivative with a mutation (V555M) in the gatekeeper residue of FGFR3 that is predicted to limit drug access to the ATP binding site [26]. Here, FGFR3 is linked to plasma cell myeloma.